Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Progen Logo
Progen Growth Score
88
CB Rank
59527
Heat Score
75
Progene is a biopharmaceutical research and development company that develops metabolic disease treatments and immune anti-cancer drugs
Founded
obfuscation
PublicPost-IPO Equity Seoul, Seoul-t'ukpyolsi, South Korea1-10 progen.co.kr/
Biotechnology
Pharmaceutical
Therapeutics
Overview

Progen
Total Funding
obfuscation
Growth Score
88
Heat Score
75

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score88
-2 pts
in past quarter
Heat Score 75
11 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About Progen

CB Rank
59527
Progene is a biopharmaceutical research and development company that develops metabolic disease treatments and immune anti-cancer drugs
Founded
obfuscation
PublicPost-IPO Equity Seoul, Seoul-t'ukpyolsi, South Korea1-10 progen.co.kr/
Biotechnology
Pharmaceutical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation

Key People

Details

Legal Name ProGen. Co., Ltd
Also Known As 프로젠
Operating Status Active
Stock Symbol  KRX:296160
Company Type For Profit
About the Company

Progene is an R&D-focused biopharmaceutical development venture that has maintained continuous collaboration and partnerships with the top pharmaceutical companies. Progene’s platform technology is a multi-target fusion protein technology, and it aims to discover various new drug candidates using this technology and create value and achieve

continuous growth through joint development or external technology transfer.

Phone Number +82-2-6098-2800
Contact Email ir@progen.co.kr
Predictions & Insights

Products & Services

PG-102
A dual agonist drug targeting GLP-1 and GLP-2 receptors for treating obesity and diabetes by improving metabolic functions and gut health.
NTIG® Platform
A multi-specific fusion protein platform technology for developing novel biopharmaceutical drugs with improved targeting and efficacy.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Progen Logo
Post-IPO Equity - Progen
5
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Progen Logo
Post-IPO Equity - Progen
5
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Progen Logo
Post-IPO Equity - Progen
5
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Progen Logo
Post-IPO Equity - Progen
5
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Progen Logo
Post-IPO Equity - Progen
5
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Progen Logo
Post-IPO Equity - Progen
5
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Progen Logo
Post-IPO Equity - Progen
5
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Progen Logo
Post-IPO Equity - Progen
5
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Progen Logo
Post-IPO Equity - Progen
5
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Progen Logo
Post-IPO Equity - Progen
5
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Susung Asset Investment Logo
Susung Asset Investment
Yes
Post-IPO Debt - Progen Logo
Post-IPO Debt - Progen
—
Susung Asset Investment Logo
Susung Asset Investment
Yes
Post-IPO Debt - Progen Logo
Post-IPO Debt - Progen
—
Susung Asset Investment Logo
Susung Asset Investment
Yes
Post-IPO Debt - Progen Logo
Post-IPO Debt - Progen
—
Susung Asset Investment Logo
Susung Asset Investment
Yes
Post-IPO Debt - Progen Logo
Post-IPO Debt - Progen
—
Susung Asset Investment Logo
Susung Asset Investment
Yes
Post-IPO Debt - Progen Logo
Post-IPO Debt - Progen
—
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 2

Employee Profiles

News

News and Press

News•May 6, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Aug 14, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,006
51.05%
 in past month

Active Website Tech Count

12Progen is actively using 12 technologies for its website, according to BuiltWith. These include SSL by Default, CommonCrawl Top 50m, and  SPF.

Total IP

16The intellectual property of Progen includes 16 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Progen's headquarters? Progen is located in Seoul, Seoul-t'ukpyolsi, South Korea.Who invested in Progen? Progen has 7 investors including Susung Asset Investment and  Young Chul Sung.When was the last funding round for Progen? Progen closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are Progen's competitors? Alternatives and possible competitors to Progen may include Strand Therapeutics, Interius BioTherapeutics, and  LIfT BioSciences.How much funding has Progen raised to date? Progen has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(8fe006b 1)
|